Cure51
Precision oncology company leveraging AI and data science to identify new cancer treatments by studying exceptional responders - patients who have unexpectedly positive responses to treatments.
Notes
Cure51 is a French precision oncology company focused on a unique approach to cancer drug discovery: studying exceptional responders. These are patients who experience unexpectedly positive outcomes from cancer treatments, providing valuable insights into potential new therapeutic approaches.
The company uses artificial intelligence and advanced data analytics to identify patterns in exceptional responders that could lead to new cancer treatments. This approach represents a paradigm shift from traditional drug discovery by starting with real-world patient outcomes rather than laboratory hypotheses.
Cure51 is part of the Sofinnova Partners portfolio, specifically within their Digital Medicine investment strategy, reflecting the company's position at the intersection of healthcare data science and oncology therapeutics.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Portfolio company of Sofinnova Partners
- Part of Sofinnova Digital Medicine Strategy
- Focus on exceptional responders in oncology
- Uses AI and data science to identify treatment patterns
- Based in Paris, France
- Represents novel approach to cancer drug discovery
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |